Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Propofol is a short-acting intravenous anesthetic agent that potentiates GABA-A receptor activity, resulting in rapid loss of consciousness through inhibition of neuronal firing in the central nervous system.
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous infusion: 20 mL/kg (4 g/kg) as a 20% solution administered over 2-4 hours. May repeat up to 100 mL/kg/day if needed.
None Documented
None Documented
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Terminal elimination half-life is approximately 1–2 hours in healthy individuals; may be prolonged in renal impairment due to accumulation of metabolites.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal excretion of unchanged drug is minimal (<5%). The majority is metabolized via the tricarboxylic acid cycle to CO2 and water. Biliary/fecal elimination is negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution